SG/CALL/GILEAD SCIENCES/80/0.1/20.12.24 | Delayed Deutsche Boerse AG 15:36:33 2024-07-10 EDT | ||
| 0.14 EUR | +7.69% |
|
| 1 month | +86.67% | ||
| 3 months | -33.33% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-10 | 0.14 | +7.69% |
| 24-07-09 | 0.13 | +8.33% |
| 24-07-08 | 0.12 | +9.09% |
| 24-07-05 | 0.11 | +10.00% |
| 24-07-04 | 0.1 | -9.09% |
Delayed Quote Deutsche Boerse AG
Last update July 10, 2024 at 03:36 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Société Générale
|
| WKN | SV457T |
| ISIN | DE000SV457T6 |
| Date issued | 2023-05-09 |
| Strike | 80 $ |
| Maturity | 2024-12-20 (163 Days) |
| Parity | 10 : 1 |
| Emission price | 1.04 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1.26 € |
|---|---|
| Lowest since issue | 0.053 € |
| Spread | 0.01 € |
| Spread % | 6.67% |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
68.75
USD
Average target price
83.23
USD
Spread / Average Target
+21.06%
- Stock Market
- Warrants
- Warrant
